15 results
P
patients with chronic lymphocytic leukemia
I/C
ibrutinib-obinutuzumab (IO), venetoclax-obinutuzumab (VO), acalabrutinib (A), acalabrutinib plus obinutuzumab (AO), IO vs VO, A vs IO, A vs VO, AO vs IO, AO vs VO
O
progression-free survival (PFS)
P
patients with elderly onset (EO) IBD, patients with adult onset (AO) IBD
I/C
systematic review and meta-analysis, EO IBD vs AO IBD
O
cumulative risk of hospitalization, surgery, mortality, treatment patterns, escalation, and/or malignancy
P
patients with peripheral arterial disease
I/C
IVUS-guided peripheral vascular interventions, angiography (AO)-guided peripheral vascular interventions
O
rates of primary patency and reintervention, rates of vascular complications, periprocedural adverse events, amputations, technical success, all-cause mortality, myocardial infarction
P
preterm newborns
I/C
high-flow nasal cannula, continuous positive airway pressure
O
therapeutic failure, nasal trauma
P
electronic cigarette users
I/C
use of electronic cigarettes, conventional cigarette experimentation and current smoking
O
risk of conventional cigarette experimentation and current smoking
P
health professionals
I/C
systematic review and meta-analysis of studies published in any language in 2020, men vs women, nurses vs physicians, front line vs non-front line workers, infected vs non-infected with coronavirus, chronic diseases vs no chronic diseases
O
prevalence of anxiety
P
care dyads, person with ostomy, caregiver
I/C
permanent discharge ostomy, no ostomy
O
rejection of bodily changes and sexual dysfunction, assertive and effective family care
P
616 participants
I/C
prednisolone/prednisone, ACTH/tetracosactide
O
electroclinical response, adverse events
P
valgus-impacted neck of femur fracture
I/C
nonoperative management, internal fixation, nonoperative management
O
displacement rate, avascular necrosis, non-union, mortality, requirement of further operative intervention
P
children
I/C
exposure to pesticides, no exposure to pesticides
O
development of astrocytomas